Linagliptin CAS 668270-12-0 Ubunyulu ≥99.0% (HPLC) Factory

Inkcazelo emfutshane:

Igama leMichiza: Linagliptin

CAS: 668270-12-0

Ubunyulu: ≥99.0% (HPLC)

Imbonakalo: Umgubo weCrystalline oMhlophe okanye oMhlophe

I-Linagliptin yonyango lohlobo lwe-II yeswekile mellitus

I-API, uMgangatho oPhezulu, iMveliso yoRhwebo

E-Mail: alvin@ruifuchem.com

Thumela i-imeyile kuthi

Iinkcukacha zeMveliso

Iimveliso ezinxulumeneyo

Iithegi zeMveliso

Inkcazo:

Ubonelelo lwabavelisi, ubunyulu obuphezulu, iMveliso yoRhwebo
Igama leMichiza: Linagliptin
CAS: 668270-12-0

Iipropati zeMichiza:

Igama leMchiza	ILinagliptin
Izithethantonye	BI-1356;8-[(3R)-3-Amino-1-piperidinyl] -7-(2-butynyl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H -purine-2,6-dione
Inombolo yeCAS	668270-12-0
Inombolo yeCAT	RF-API105
Ubume beStokhwe	Kwi-Stock, iMveliso yoMveliso ukuya kwiiToni
Ifomula yeemolekyuli	C25H28N8O2
Ubunzima beMolekyuli	472.54
Indawo yokunyibilika	197.0 ukuba 200.0℃
Ukunyibilika	Inyibilika kwi-DMSO
Uphawu	Ruifu Chemical

Iinkcukacha:

Into	Iinkcukacha
Imbonakalo	Umgubo weCrystalline oMhlophe okanye oMhlophe
NMR	Ukungqinelana Nolwakhiwo
Ubunyulu / Indlela yokuHlalutya	≥99.0% (HPLC)
Ilahleko ekomisweni	≤0.50%
Intsalela kwi-Ignition	≤0.10%
Iintsimbi ezinzima	≤10ppm
Izinto ezinxulumeneyo
Ukungacoceki Okukodwa	≤0.50%
Ukungcola ngokupheleleyo	≤1.0%
Isomer	≤0.15%
Izinyibilikisi ezishiyekileyo
IMethanol	≤3000ppm
Isopropanol	≤5000ppm
I-DMF	≤800ppm
Dichloromethane	≤600ppm
Umgangatho woVavanyo	Umgangatho woShishino
Ukusetyenziswa	API

Ukupakishwa kunye noGcino:

Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, 25kg/Igubu lekhadibhodi, okanye ngokwemfuno yomthengi.

Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ukukhanya kunye nokufuma.

Izinto eziluncedo:

FAQ:

Isicelo:

I-Linagliptin (i-CAS: 668270-12-0) i-DPP-4 inhibitor eyenziwe ngu-Boehringer Ingelheim yonyango lwe-type II yeswekile.Iimpawu ezimbini ze-pharmacological ezenza i-linagliptin ihluke kwezinye i-DPP-4 inhibitors kukuba ineprofayili ye-pharmacokinetic engekho mgca kwaye ayipheli ngokuyintloko yinkqubo yezintso.I-Linagliptin (kanye ngemini) yamkelwa yi-US FDA nge-2 kaMeyi ka-2011 kunyango lwe-type II yeswekile.Ithengiswa nguBoehringer Ingelheim kunye noLilly.ILinagliptin, ithengiswa phantsi kwegama lebrendi iTradjenta phakathi kwabanye.Isetyenziswa kunye nemithambo kunye nokutya.